Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 505-508

  Del Mastro, L ^a   Venturini, M ^c   Viscoli, C ^c   Bergaglio, M ^c   Signorini, A ^c   Bighin, C ^c   Bertelli, G ^c   Semino, C ^a   Pietra, G ^a   Bertoglio, S ^c   Sertoli, M R ^c   Lambiase, A ^b   Rosso, R ^c   Melioli, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b ROCHE MILANO RICERCHE   (Italy)

^c NONE

Author keywords

Adverse effects; Colony stimulating factors; Cryopreservation; Dimethyl sulfoxide

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEASE; DIMETHYL SULFOXIDE; EPIRUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DIGESTION; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INFUSION; MAXIMUM TOLERATED DOSE; METHODOLOGY; NAUSEA AND VOMITING; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA;

EID: 0035019294     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011123218220     Document Type: Article

References (12)

1. Smith DM, Weisenburger DD, Bierman P et al. Acute renal failure associated with autologous bone marrow tranplantation. Bone Marrow Transplant 1987; 2: 195-201.
2. Vriesendorp R, Aalders JC, Sleijfer T et al. Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. Gynecol Oncol 1984; 17: 271-6.
3. O'Donnell JR, Burnett AK, Sheehan T et al. Safety of dimethyl-sulfoxide. Lancet 1981; 1: 498.
4. Davis JM, Rowley SD, Braine HG et al. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990; 75 (3): 781-6.
5. Okamoto Y, Takaue Y, Saito S et al. Toxicities associated with cryopreserved and thawed peripheral blood stem-cell autografts in children with active cancer. Transfusion 1993; 33: 578-81.
6. Dhodapkar M, Goldberg SL, Tefferi A, Gertz MA. Reversible encephalopathy after cryopreserved peripheral blood stem-cell infusion. Am J Hematol 1994; 45 (2): 187-8.
7. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 1998; 16 (3): 1179-87.
8. Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. Br J Haematol 1998; 102 (4): 879-88.
9. Venturini M, Del Mastro L, Melioli G et al. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy. Cancer 1994; 74 (8): 2300-6.
10. Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 1995; 31A (12): 2013-22.
11. Zambelli A, Poggi G, Da Prada GA et al. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res 1998; 18: 4705-8.
12. Essayan DM, Schilder R, Kagey-Sobotka A et al. Anaphylaxis during autologous peripheral blood progenitor cell infusion. Bone Marrow Transplant 1997; 19 (7): 749-52.